One of the most promising types of immunotherapy uses adoptive cell transfer (ACT). While all types of ACT are in their early days of development relatively speaking, one method showing great potential is chimeric antigen receptor T-cell therapy, or CAR-T.
One of the most innovative platforms that BioAgilytix maintains is the BD FACSLyric™. This flow cytometer is used when very accurate measurement of cellular biomarkers in complex subpopulations is necessary.
BioAgilytix is committed to keeping on the pulse of bioanalytical innovation across the pharmaceutical and biotechnology industries. To that end, we’d like to share some of the industry headlines we’ve been most interested in recently.
In this Q&A session, we get to know Daniel Cohen, Business Development Director, Mid-Atlantic and Asia, at BioAgilytix, as he discusses how his work has changed and evolved as the company has grown over the last six years.
Platforms
Services